775 related articles for article (PubMed ID: 15922062)
1. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
Iancu R; Mohapel P; Brundin P; Paul G
Behav Brain Res; 2005 Jul; 162(1):1-10. PubMed ID: 15922062
[TBL] [Abstract][Full Text] [Related]
2. Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease.
Ogura T; Ogata M; Akita H; Jitsuki S; Akiba L; Noda K; Hoka S; Saji M
Neurosci Res; 2005 Mar; 51(3):299-308. PubMed ID: 15710494
[TBL] [Abstract][Full Text] [Related]
3. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
[TBL] [Abstract][Full Text] [Related]
4. Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys.
Henderson JM; Stanic D; Tomas D; Patch J; Horne MK; Bourke D; Finkelstein DI
Behav Brain Res; 2005 May; 160(2):267-76. PubMed ID: 15863223
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
6. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
7. Sexually dimorphic postural adjustments during vertical behaviour are altered in a unilateral 6-OHDA rat model of Parkinson's disease.
Field EF; Metz GA; Pellis SM; Whishaw IQ
Behav Brain Res; 2006 Nov; 174(1):39-48. PubMed ID: 16930735
[TBL] [Abstract][Full Text] [Related]
8. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion.
Sindhu KM; Saravanan KS; Mohanakumar KP
Brain Res; 2005 Jul; 1051(1-2):25-34. PubMed ID: 15992782
[TBL] [Abstract][Full Text] [Related]
9. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
10. Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.
Metz GA; Piecharka DM; Kleim JA; Whishaw IQ
Brain Res; 2004 Nov; 1026(1):126-35. PubMed ID: 15476704
[TBL] [Abstract][Full Text] [Related]
11. The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis.
Metz GA; Tse A; Ballermann M; Smith LK; Fouad K
Eur J Neurosci; 2005 Aug; 22(3):735-44. PubMed ID: 16101755
[TBL] [Abstract][Full Text] [Related]
12. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R
Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202
[TBL] [Abstract][Full Text] [Related]
13. Dose-dependent loss of motor function after unilateral medial forebrain bundle rotenone lesion in rats: a cautionary note.
Klein A; Gidyk DC; Shriner AM; Colwell KL; Tatton NA; Tatton WG; Metz GA
Behav Brain Res; 2011 Sep; 222(1):33-42. PubMed ID: 21419806
[TBL] [Abstract][Full Text] [Related]
14. Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
Willis GL; Kelly AM; Kennedy GA
Behav Brain Res; 2008 Nov; 193(1):37-47. PubMed ID: 18547659
[TBL] [Abstract][Full Text] [Related]
15. Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease.
Reglodi D; Lubics A; Tamás A; Szalontay L; Lengvári I
Behav Brain Res; 2004 May; 151(1-2):303-12. PubMed ID: 15084446
[TBL] [Abstract][Full Text] [Related]
16. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats.
Winter C; von Rumohr A; Mundt A; Petrus D; Klein J; Lee T; Morgenstern R; Kupsch A; Juckel G
Behav Brain Res; 2007 Dec; 184(2):133-41. PubMed ID: 17698212
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
[TBL] [Abstract][Full Text] [Related]
18. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
[TBL] [Abstract][Full Text] [Related]
19. Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat.
Moore AE; Cicchetti F; Hennen J; Isacson O
Exp Neurol; 2001 Dec; 172(2):363-76. PubMed ID: 11716560
[TBL] [Abstract][Full Text] [Related]
20. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
